Understanding and Alleviating Healthcare System Pressure: A Conceptual Framework

By Staff Writer

February 14, 2024

Introduction:

The COVID-19 pandemic has highlighted the devastating effects of resource scarcity in healthcare systems. This emphasises the need to understand and ease Healthcare System Pressure (HCSP). While there’s no official HCSP definition, the Office of Health Economics (OHE) has developed and examined a conceptual framework for HCSP. It includes a broad definition and concepts of HCSP, strategies to lessen HCSP, and a system for metric categorisation.

Understanding Healthcare System Pressure:

Long before the COVID-19 pandemic, healthcare systems were feeling the strain. This is evident in the UK, where increasing waiting lists and treatment times are common. Yet, the term ‘pressure’ lacks a clear definition in the healthcare context. When healthcare systems face strain, they behave differently than in normal conditions. This strain could lead to an inability to provide emergency care or delay planned care. Moreover, the quality of care might suffer due to continuous pressure on staff. This can lead to staff burnout and poorer health outcomes for patients.

The Conceptual Framework of HCSP:

The primary exposure of hospital settings to increased patient demand in the event of seasonal diseases or pandemics was the driving force for the decision to concentrate on HCSP in hospital settings. It was the findings of the review that served as the basis for the construction of each individual component of the conceptual framework. They also conducted a ‘proof-of-concept’ exercise utilising expert interviews from Germany, Italy and the UK to test the comprehensiveness and usefulness of this framework, using respiratory syncytial virus (RSV) and Clostridioides difficile (C. difficile) infections as case studies.

Universally Accepted Definition of HCSP:

HCSP can affect different types of resources that can be categorised into ‘staff’ (i.e., labour resources), ‘stuff’ (i.e., durable equipment) and ‘structures’ (physical infrastructure within the hospital). A resource has a usable capacity, which is the amount of capacity available for production in normal circumstances. The usable capacity can be split into utilised capacity, which is actually used for production, and idle capacity, which remains unused. Using the concepts of resources, capacity, and utilisation, HCSP can be described as occurring when the demand determining the utilised capacity of a resource exceeds its usable capacity (Figure 1).

Alleviating HCSP:

Keeping bed occupancy below 85% is crucial for hospitals to operate safely and effectively, as seen in the English National Health System (NHS). This framework identifies two main actions to alleviate HCSP: increasing the usable capacity to accommodate higher demand levels and expanding the usable capacity as a pressure-mitigating action. These actions are linked to the concept of surge capacity, which is predominantly applied within the field of disaster management.

Classifying HCSP Metrics:

The OHE found no consensus on the metrics of HCSP and its opportunity costs. However, for each resource, HCSP can be measured using usable and utilised capacity metrics. Routinely collected key performance indicators (KPIs) in hospital finance, procedures, and staff provide multiple pressure measurement alternatives. Some KPIs directly measure resource utilisation (e.g. bed occupancy and average length of stay), while others indirectly indicate pressure (e.g. staff turnover or waiting times). This can impact quality indicators and outcomes, such as mortality rates.

Conclusion:

The proposed framework may have beneficial and practical applications. We could use the HCSP formulation to evaluate health technologies that reduce pressure on the healthcare system. This evaluation forms part of the health technology assessment (HTA). The goal of HTA is to guide the efficient use of limited healthcare resources. This becomes crucial in high-strain situations like those seen in the NHS, leading to elective surgery cancellations and potential medical care rationing. Traditional HTA approaches may underestimate HCSP-easing health innovations such as vaccinations. This is because of the large elective care backlogs and the high potential cost of delayed treatment.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

đź’ˇ *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.